QUEST DIAGNOSTICS INC is expected to release its Q3 2026 10-Q filing on October 19, 2026, before market open. Last quarter: Quest Diagnostics delivered 10.2% revenue growth and 13.5% net-income growth in Q2 FY2026, led by higher Diagnostic Information Services testing volume, although lower revenue per requisition and higher service costs reduced operating margin to 15.1%.
EPS Estimate
$2.83
Revenue Estimate
$3.04B
Analyst consensus from Finnhub. Actual results posted within minutes of the SEC filing on the DGX page.
Drawn from management commentary in the Q2 2026 10-Q:
Total net revenues increased 10.2% to $3.043B, principally driven by 10.0% organic revenue growth; Diagnostic Information Services (DIS), which represents more than 95% of consolidated revenue, increased 10.3% to $2.978B, while Diagnostic Solutions revenue rose 4.3% to $65M.
DIS requisition volume increased 13.1%, including approximately 9 percentage points from the Corewell Health Collaborative Lab Solutions relationship and increased testing at Fresenius Medical Care dialysis clinics. Revenue per requisition declined 2.8% because these relationships have a greater proportion of routine tests; excluding their mix effect, revenue per requisition increased approximately 3%.
Operating income increased 4.6% to $459M, slower than revenue growth, as cost of services increased $198M, or 10.9%, primarily from higher compensation costs and higher supplies expense associated with testing volume. SG&A rose $43M, or 9.0%, also primarily due to higher compensation costs; operating margin declined to 15.1% from 15.9%.
Revenue
$3.04B
++10.21% YoY
EPS (Basic)
$2.88
++14.74% YoY
Operating Income
$459M
++4.79% YoY
Add DGX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.